Trials / Recruiting
RecruitingNCT06241781
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
A Phase 2, Multicenter Randomized Controlled Open-label Study of Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 83 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT101 injection | GT101 injection to treat cervical cancer |
| DRUG | Gemcitabine injection | Gemcitabine injection to treat cervical cancer |
Timeline
- Start date
- 2024-04-02
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
- First posted
- 2024-02-05
- Last updated
- 2026-04-15
Locations
24 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06241781. Inclusion in this directory is not an endorsement.